Have your own idea? Try our Stock Screener
Polish (WIG) Pharma Industry Analysis
UpdatedApr 15, 2025
DataAggregated Company Financials
Companies6
- 7D0.9%
- 3M-3.2%
- 1Y28.6%
- YTD-5.6%
Over the last 7 days, the Pharma industry has dropped 3.2%, driven by declines in Molecure and Celon Pharma of 6.5% and 0.8%, respectively. Meanwhile, Cannabis Poland actually outperformed within the industry, gaining 5.6% in the last week. In the past year, the industry has gained 26%. Looking forward, earnings are forecast to decline by 30% per year.
Industry Valuation and Performance
Has the Polish Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 15 Apr 2025 | zł1.6b | zł324.0m | -zł12,792,856.00 | 43.6x | -125.2x | 4.9x |
| Thu, 13 Mar 2025 | zł1.7b | zł322.6m | -zł12,258,563.00 | 47.5x | -141x | 5.4x |
| Sat, 08 Feb 2025 | zł1.6b | zł318.9m | -zł9,295,998.00 | 42.9x | -169.7x | 4.9x |
| Mon, 06 Jan 2025 | zł1.7b | zł318.9m | -zł9,295,998.00 | 44.5x | -182.2x | 5.3x |
| Wed, 04 Dec 2024 | zł1.7b | zł360.7m | -zł14,404,163.00 | 44.3x | -120.1x | 4.8x |
| Fri, 01 Nov 2024 | zł1.7b | zł314.5m | -zł72,767,518.00 | 10.7x | -24x | 5.6x |
| Sun, 29 Sep 2024 | zł1.8b | zł314.9m | -zł71,339,104.00 | 11.4x | -25.5x | 5.8x |
| Tue, 27 Aug 2024 | zł2.1b | zł317.1m | -zł60,161,675.00 | 10.9x | -34.4x | 6.5x |
| Thu, 25 Jul 2024 | zł1.9b | zł310.8m | -zł61,217,640.00 | 11.7x | -31x | 6.1x |
| Sat, 22 Jun 2024 | zł1.1b | zł310.8m | -zł61,217,640.00 | 12x | -18.6x | 3.7x |
| Mon, 20 May 2024 | zł1.2b | zł315.1m | -zł43,109,632.00 | 12.4x | -28x | 3.8x |
| Wed, 17 Apr 2024 | zł1.1b | zł311.5m | -zł40,173,065.00 | 15.1x | -28.3x | 3.6x |
| Fri, 15 Mar 2024 | zł1.2b | zł311.5m | -zł40,173,065.00 | 15.2x | -29.8x | 3.8x |
| Sun, 11 Feb 2024 | zł1.2b | zł307.4m | -zł40,479,653.00 | 18x | -29.9x | 3.9x |
| Tue, 09 Jan 2024 | zł1.2b | zł308.7m | -zł39,880,934.00 | 11.7x | -30.2x | 3.9x |
| Thu, 07 Dec 2023 | zł1.2b | zł308.7m | -zł39,880,934.00 | 11.2x | -30.6x | 3.9x |
| Sat, 04 Nov 2023 | zł1.1b | zł302.0m | -zł44,782,495.00 | 11.2x | -25x | 3.7x |
| Mon, 02 Oct 2023 | zł1.1b | zł302.0m | -zł42,933,291.00 | 10.5x | -26.2x | 3.7x |
| Wed, 30 Aug 2023 | zł1.3b | zł287.0m | -zł53,882,152.00 | 11.4x | -23.4x | 4.4x |
| Fri, 28 Jul 2023 | zł1.2b | zł278.4m | -zł53,806,540.00 | 36.6x | -22.2x | 4.3x |
| Sun, 25 Jun 2023 | zł1.2b | zł278.4m | -zł53,806,540.00 | 36.7x | -22.1x | 4.3x |
| Tue, 23 May 2023 | zł1.1b | zł280.8m | -zł51,259,182.00 | 8.7x | -21.5x | 3.9x |
| Thu, 20 Apr 2023 | zł1.1b | zł273.2m | -zł44,427,333.00 | 8.7x | -24.5x | 4x |
| Sat, 18 Mar 2023 | zł1.1b | zł273.2m | -zł44,427,333.00 | 8.5x | -25.2x | 4.1x |
| Mon, 13 Feb 2023 | zł1.1b | zł270.3m | -zł44,201,704.00 | 7.7x | -25.9x | 4.2x |
| Wed, 11 Jan 2023 | zł1.0b | zł270.3m | -zł44,201,704.00 | 7.6x | -22.9x | 3.7x |
| Fri, 09 Dec 2022 | zł1.1b | zł270.3m | -zł44,201,704.00 | 7.6x | -24.7x | 4x |
| Sun, 06 Nov 2022 | zł978.0m | zł260.7m | -zł40,809,798.00 | 8.4x | -24x | 3.8x |
| Tue, 04 Oct 2022 | zł888.4m | zł261.1m | -zł40,391,998.00 | 9.4x | -22x | 3.4x |
| Thu, 01 Sep 2022 | zł1.0b | zł265.7m | -zł29,303,736.00 | 9.1x | -34.2x | 3.8x |
| Sat, 30 Jul 2022 | zł1.2b | zł264.2m | -zł29,985,890.00 | 11x | -38.4x | 4.4x |
| Mon, 27 Jun 2022 | zł1.0b | zł264.2m | -zł29,985,890.00 | 10x | -34.5x | 3.9x |
| Wed, 25 May 2022 | zł1.4b | zł269.1m | -zł24,188,890.00 | 10.7x | -56.4x | 5.1x |
| Fri, 22 Apr 2022 | zł1.7b | zł235.3m | -zł1,158,483.00 | 62.8x | -1508.8x | 7.4x |
Price to Earnings Ratio
-1508.8x
Current Industry PE
- Investors are relatively neutral on the Polish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Polish Healthcare industry?
| PL Market | 6.77% | |
| Healthcare | 4.76% | |
| Pharma | 0.87% | |
| Pharma | 0.87% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CLN Celon Pharma | zł24.80 | 2.1% +zł26.9m | 65.3% | PE72.2x | |
| CBD Cannabis Poland | zł0.35 | 5.6% +zł910.3k | -39.0% | PS68.5x |